Unicycive Therapeutics Inc (UNCY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Unicycive Therapeutics Inc (UNCY) has a cash flow conversion efficiency ratio of -0.159x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.96 Million) by net assets ($37.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Unicycive Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Unicycive Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read UNCY liabilities breakdown for a breakdown of total debt and financial obligations.
Unicycive Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Unicycive Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MKH Bhd
KLSE:6114
|
0.032x |
|
De Licacy Industrial Co Ltd
TW:1464
|
0.054x |
|
Imperial Petroleum Inc
NASDAQ:IMPP
|
0.035x |
|
VenueG Co. Ltd
KQ:019010
|
0.015x |
|
Lithium Ionic Corp
V:LTH
|
-0.114x |
|
NOVONIX LTD SP.ADS/4
F:GC30
|
N/A |
|
MOLECULAR PARTNERS ADS/1
F:6ML0
|
-0.139x |
|
Endomines Finland Oyj
HE:PAMPALO
|
0.142x |
Annual Cash Flow Conversion Efficiency for Unicycive Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Unicycive Therapeutics Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Unicycive Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.43 Million | $-28.57 Million | -3.845x | -180.11% |
| 2023-12-31 | $-3.81 Million | $-18.28 Million | 4.800x | -85.71% |
| 2022-12-31 | $-466.00K | $-15.65 Million | 33.586x | +9699.95% |
| 2021-12-31 | $16.48 Million | $-5.77 Million | -0.350x | -164.05% |
| 2020-12-31 | $-2.67 Million | $-1.46 Million | 0.546x | -58.94% |
| 2019-12-31 | $-884.00K | $-1.18 Million | 1.330x | +107.01% |
| 2018-12-31 | $-1.21 Million | $-775.00K | 0.643x | -- |
About Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease… Read more